Concepts (144)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intraocular Pressure | 8 | 2021 | 128 | 0.560 |
Why?
|
| Glaucoma, Open-Angle | 5 | 2021 | 36 | 0.440 |
Why?
|
| Cloprostenol | 2 | 2009 | 4 | 0.370 |
Why?
|
| Prostaglandins F, Synthetic | 1 | 2009 | 3 | 0.310 |
Why?
|
| Prostaglandins, Synthetic | 1 | 2009 | 3 | 0.310 |
Why?
|
| Antihypertensive Agents | 2 | 2009 | 430 | 0.290 |
Why?
|
| Trabeculectomy | 3 | 2016 | 15 | 0.240 |
Why?
|
| Glaucoma | 3 | 2016 | 79 | 0.240 |
Why?
|
| Veterans | 3 | 2021 | 1763 | 0.220 |
Why?
|
| Ophthalmology | 2 | 2016 | 198 | 0.200 |
Why?
|
| Internship and Residency | 3 | 2016 | 1258 | 0.180 |
Why?
|
| Contact Lenses | 1 | 2020 | 42 | 0.170 |
Why?
|
| Diabetic Retinopathy | 1 | 2023 | 168 | 0.170 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2023 | 277 | 0.170 |
Why?
|
| Corneal Diseases | 1 | 2020 | 95 | 0.160 |
Why?
|
| Optic Neuritis | 3 | 2004 | 34 | 0.150 |
Why?
|
| Gout | 1 | 2021 | 167 | 0.140 |
Why?
|
| Intraoperative Complications | 2 | 2016 | 160 | 0.140 |
Why?
|
| Reoperation | 3 | 2016 | 852 | 0.140 |
Why?
|
| Timolol | 2 | 2009 | 9 | 0.140 |
Why?
|
| Accidental Falls | 1 | 2018 | 115 | 0.130 |
Why?
|
| Lens Implantation, Intraocular | 2 | 2016 | 216 | 0.130 |
Why?
|
| Macular Degeneration | 1 | 2018 | 127 | 0.130 |
Why?
|
| Visual Acuity | 5 | 2018 | 707 | 0.130 |
Why?
|
| Vision Disorders | 1 | 2018 | 217 | 0.130 |
Why?
|
| Hospitals, Veterans | 3 | 2018 | 348 | 0.120 |
Why?
|
| Medical Staff, Hospital | 1 | 2016 | 98 | 0.120 |
Why?
|
| Anterior Chamber | 1 | 2015 | 33 | 0.120 |
Why?
|
| Phacoemulsification | 1 | 2016 | 147 | 0.110 |
Why?
|
| Inpatients | 1 | 2018 | 553 | 0.110 |
Why?
|
| Cataract Extraction | 1 | 2015 | 152 | 0.110 |
Why?
|
| Filtering Surgery | 1 | 2013 | 4 | 0.100 |
Why?
|
| Silver | 1 | 2013 | 29 | 0.100 |
Why?
|
| Surgically-Created Structures | 1 | 2013 | 5 | 0.100 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2013 | 67 | 0.100 |
Why?
|
| Metal Nanoparticles | 1 | 2013 | 56 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 1418 | 0.100 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2013 | 50 | 0.100 |
Why?
|
| Travoprost | 2 | 2009 | 2 | 0.090 |
Why?
|
| Multiple Sclerosis | 3 | 2004 | 382 | 0.090 |
Why?
|
| Ophthalmic Solutions | 2 | 2009 | 90 | 0.090 |
Why?
|
| Retrospective Studies | 8 | 2023 | 17395 | 0.090 |
Why?
|
| Aged | 10 | 2020 | 21482 | 0.080 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 564 | 0.080 |
Why?
|
| Aged, 80 and over | 5 | 2018 | 7138 | 0.080 |
Why?
|
| Thiazines | 1 | 2009 | 2 | 0.080 |
Why?
|
| Hyperemia | 1 | 2009 | 35 | 0.080 |
Why?
|
| Middle Aged | 10 | 2023 | 29021 | 0.080 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2009 | 27 | 0.070 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2009 | 77 | 0.070 |
Why?
|
| Thiophenes | 1 | 2009 | 69 | 0.070 |
Why?
|
| Blindness | 1 | 2009 | 76 | 0.070 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2009 | 223 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 749 | 0.070 |
Why?
|
| Sulfonamides | 1 | 2009 | 284 | 0.070 |
Why?
|
| Postoperative Complications | 2 | 2016 | 3139 | 0.060 |
Why?
|
| Male | 14 | 2023 | 65012 | 0.060 |
Why?
|
| Prospective Studies | 5 | 2021 | 6568 | 0.060 |
Why?
|
| Visual Fields | 2 | 2004 | 145 | 0.060 |
Why?
|
| Female | 15 | 2023 | 70785 | 0.060 |
Why?
|
| Adult | 9 | 2020 | 31614 | 0.050 |
Why?
|
| Humans | 18 | 2023 | 132247 | 0.050 |
Why?
|
| Contrast Sensitivity | 1 | 2004 | 43 | 0.050 |
Why?
|
| Disability Evaluation | 1 | 2004 | 198 | 0.050 |
Why?
|
| Endothelial Growth Factors | 1 | 2023 | 53 | 0.050 |
Why?
|
| Aspirin | 1 | 2004 | 220 | 0.050 |
Why?
|
| Bevacizumab | 1 | 2023 | 80 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2021 | 3414 | 0.050 |
Why?
|
| Primary Health Care | 1 | 2009 | 801 | 0.050 |
Why?
|
| Ranibizumab | 1 | 2023 | 76 | 0.050 |
Why?
|
| Intravitreal Injections | 1 | 2023 | 154 | 0.050 |
Why?
|
| Administration, Topical | 2 | 2013 | 140 | 0.040 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2023 | 226 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2004 | 387 | 0.040 |
Why?
|
| Prosthesis Fitting | 1 | 2020 | 11 | 0.040 |
Why?
|
| Treatment Outcome | 5 | 2020 | 13027 | 0.040 |
Why?
|
| Sclera | 1 | 2020 | 41 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 444 | 0.040 |
Why?
|
| Cornea | 1 | 2004 | 569 | 0.040 |
Why?
|
| Optic Chiasm | 1 | 1999 | 14 | 0.040 |
Why?
|
| Clinical Competence | 2 | 2016 | 1078 | 0.040 |
Why?
|
| Sarcoidosis | 1 | 1999 | 58 | 0.040 |
Why?
|
| Pseudotumor Cerebri | 1 | 1999 | 66 | 0.030 |
Why?
|
| Papilledema | 1 | 1999 | 83 | 0.030 |
Why?
|
| Optic Nerve Diseases | 1 | 1999 | 85 | 0.030 |
Why?
|
| Ocular Hypertension | 2 | 2009 | 24 | 0.030 |
Why?
|
| Aging | 1 | 2004 | 1254 | 0.030 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 2 | 2009 | 83 | 0.030 |
Why?
|
| Risk Factors | 3 | 2021 | 10945 | 0.030 |
Why?
|
| Drug Combinations | 2 | 2009 | 280 | 0.030 |
Why?
|
| Corneal Edema | 1 | 2015 | 11 | 0.030 |
Why?
|
| Operating Rooms | 1 | 2016 | 79 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2018 | 1255 | 0.030 |
Why?
|
| Cohort Studies | 3 | 2016 | 5176 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 94 | 0.030 |
Why?
|
| Operative Time | 1 | 2016 | 192 | 0.030 |
Why?
|
| Macular Edema | 1 | 2015 | 96 | 0.030 |
Why?
|
| Logistic Models | 1 | 2018 | 1841 | 0.030 |
Why?
|
| Blister | 1 | 2013 | 22 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 1128 | 0.030 |
Why?
|
| Double-Blind Method | 2 | 2009 | 1653 | 0.030 |
Why?
|
| Mitomycin | 1 | 2013 | 53 | 0.030 |
Why?
|
| Antimetabolites | 1 | 2013 | 30 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2013 | 128 | 0.020 |
Why?
|
| Rabbits | 1 | 2013 | 673 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 1008 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 3376 | 0.020 |
Why?
|
| United States | 3 | 2018 | 11669 | 0.020 |
Why?
|
| Tonometry, Ocular | 1 | 2009 | 23 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2018 | 3736 | 0.020 |
Why?
|
| Inflammation | 1 | 2015 | 1522 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2004 | 3853 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2009 | 570 | 0.010 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 2004 | 17 | 0.010 |
Why?
|
| Body Weights and Measures | 1 | 2004 | 39 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2004 | 5410 | 0.010 |
Why?
|
| Safety | 1 | 2005 | 216 | 0.010 |
Why?
|
| Joint Diseases | 1 | 2004 | 34 | 0.010 |
Why?
|
| Vision Tests | 1 | 2004 | 29 | 0.010 |
Why?
|
| Methylprednisolone Hemisuccinate | 1 | 2003 | 5 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2004 | 135 | 0.010 |
Why?
|
| Health Status Indicators | 1 | 2004 | 127 | 0.010 |
Why?
|
| Prednisone | 1 | 2003 | 253 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 4690 | 0.010 |
Why?
|
| Heart Rate | 1 | 2005 | 584 | 0.010 |
Why?
|
| Radiography | 1 | 2004 | 818 | 0.010 |
Why?
|
| Brain | 2 | 2004 | 3194 | 0.010 |
Why?
|
| Adolescent | 3 | 2004 | 20557 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2003 | 305 | 0.010 |
Why?
|
| Acute Disease | 1 | 2003 | 1163 | 0.010 |
Why?
|
| Recurrence | 1 | 2004 | 1453 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2004 | 1161 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2005 | 1402 | 0.010 |
Why?
|
| Sex Factors | 1 | 2003 | 1354 | 0.010 |
Why?
|
| Disease Progression | 1 | 2004 | 2233 | 0.010 |
Why?
|
| Young Adult | 1 | 2009 | 9966 | 0.010 |
Why?
|
| Quality of Life | 1 | 2004 | 2161 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2004 | 3995 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1999 | 1966 | 0.010 |
Why?
|
| Animals | 1 | 2013 | 34850 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2004 | 2087 | 0.010 |
Why?
|
| Infant | 1 | 2004 | 13049 | 0.000 |
Why?
|
| Child, Preschool | 1 | 2004 | 14736 | 0.000 |
Why?
|
| Child | 1 | 2004 | 25783 | 0.000 |
Why?
|